A recent study by researchers at the Sanford-Burnham Medical Research Institute found a connection between the B and T lymphocyte attenuator (BTLA) inhibitory receptor in reducing inflammatory effects, particularly in the skin.
The results of the study, published in the journal Immunity, could contribute to the future development of new treatments for a number of inflammatory responses such as Psoriasis, Crohn’s Disease and Arthritis.
While any new research is promising, the applicability to direct patient care usually comes years after the breakthrough. The findings in the Sanford-Burnham study are exciting, but the benefits were exhibited in a small test group of lab animals and have yet to be fully tested for negative repercussions.
The best path for a patient dealing with the day-to-day effects of inflammatory diseases is to follow doctor’s guidance to control outbreaks and manage pain. In addition, another alternative is to consider participating in a clinical trial. The clinical trials running today are the safe, tested breakthroughs of yesterday that shape the course for future developments.